To Study the Prevalence of Thyroid Dysfunction in Patients of Type II Diabetes Mellitus

Abstract

Introduction: Diabetes mellitus (DM) and thyroid dysfunction (TD) are the two most common endocrine disorders in clinical practice. The unrecognized TD may adversely affect the metabolic control and add more risk to an already predisposing scenario for cardiovascular diseases. T Material and methods: 100 patients with T2DM were selected from the Outpatient department and admitted in Inpatient department of Medicine in Subharti Medical College Meerut, participated in the study. Thyroid dysfunction was classified as Subclinical hypothyroidism (SCH) was defined as TSH-4.5 to 10 mIU/ml with normal FT4. Overt hypothyroidism-TSH >10 mIU/ml with low FT4. Hyperthyroidism-<0.45 mIU/ ml TSH with raised FT4 Subclinical hyperthyroidism-<0.45 mIU/ml TSH with normal FT4. Result:The prevalence of Thyroid Dysfunction in all diabetic patients was 24%.function was 24% (16% had subclinical hypothyroidism, 6% of patients had overt hypothyroidism and only 2% of patients had overt hyperthyroidism Conclusion:Our study emphasizes the need to check TSH levels in all type 2 diabetic patients, as subclinical hypothyroidism was most prevalent thyroid dysfunction in patients with diabetes.

A Cross- Sectional Study Regarding Assessment of Microvascular Complications Among Type 2 Diabetes Mellitus Patients at One of the Tertiary Care Hospitals in Northern India.

“…13 14 This is similar to the studies of Fawwad A et al , Jain SK et al , 15 16 Kulshrestha M et al and Cheema S et al . 14 Jain SK et al observational cross-sectional study found patients presenting with diabetic complications of retinopathy, nephropathy and neuropathy were 30%, 47%, and 23% respectively. Fundus examination revealed that 28 cases had non-proliferative diabetic retinopathy and two cases had proliferative retinopathy and it was statistically significant.…”

Antidiabetic Potency of Flavonoids Using a Systematic Computer-Aided Drug Design Platform

“…Apart from all types, nearly 90% of adults suffer from type 2 diabetes (T2DM), which disproportionately affects low-and middle-income continents like Africa and Asia due to food habits and lifestyles. As per current reports of the World Health Organization (WHO) and the International Diabetic Federation (IDF), the global T2DM cases will cross 560 million by 2045 (WHO, 2022;Cloete et al, 2022;Sarkar et al, 2023;Lancet, 2023;Tyagi et al, 2024). A variety of medications preferable to insulin are available, but the rapid increase in T2DM cases indicates newer potential drugs with new strategies of treatment modalities are urgently required (Grover and Utreja, 2014;Padhi et al, 2020;Sur et al, 2023;Biswas et al, 2023).…”